Connect with the Synthetic Biology Global Community

Are you a part of the synthetic biology industry? A company representative aiming to wow your future customers? A venture capitalist looking for their next unicorn? An entrepreneur pitching to investors? Or an academic with a technology or patent and an urge to commercialise it? Whether your focus is industrial, financial, or academic, SynBioBeta London 2016 is the premiere synthetic biology conference for the industry – bringing the global community together to share best practices and learn.

With a program full of talks from key thought-leaders, decision makers and tech pioneers, SynBioBeta is a must for those wanting to keep up with the rapidly-evolving industry. Networking opportunities are rich for those aiming to grow their company, their client list, or launch their next product – many a fruitful partnership, connection, or new venture has been started at our conferences. If you are an active part of the synthetic biology industry and have a passion for making biology easier to engineer, then this is a must attend event.

Who Should Attend?

  • Tech Practitioners: Hear about the latest technology, spot the upcoming trends, and meet the key people busily building the future.
  • Industry and Start-ups: Get critical opportunities to network, exhibit, and make the connections that you and your company need to grow.
  • Investors and Angels: Keep a finger on the pulse of technological development, and meet founders and investors as you hunt for your next unicorn.
  • Technology Scouts: Learn who the leading lights are in each segment, identify value-adding technologies, and lay the groundwork for further deals.
  • Academics:  Gain access to professionals ranging from eager potential cofounders to sagely experienced entrepreneurs and well-connected investors.
  • Students and Biohackers: Get yourself involved by meeting industry leaders and laying the groundwork for your community connections.

SynBioBeta Activate! Edinburgh 2016

Date & Location:

April 6, 2016 - April 8, 2016
12:00 pm - 6:00 pm

Imperial College London
Venue Information

Hear from Previous SynBioBeta Attendees

Testimonials

Michael Roberts

“SynBioBeta has firmly established itself as a must attend event for UK synthetic biology companies”

Michael Roberts, Synpromics

Bethan Wolfenden

“We made several valuable connections, including to two potential investors, and a number of future customers.”

Bethan Wolfenden,
Bento Bioworks

Lionel Clarke

“SynBioBeta brings together many of the most innovative minds in the field of Synthetic Biology, sharing their enthusiasm and energy for turning ideas into reality.”

Lionel Clarke, Co-Chair
UK Synthetic Biology Leadership Council

Sponsors:

Gold

Silver

Bronze

Event Hosts:

Featured Speakers

Alexandra Daisy Ginsberg

Alexandra Daisy Ginsberg
Royal College of Art

Barbara Harvey

Barbara Harvey
Novozymes

Ena Cratsenburg

Ena Cratsenburg
Intrexon

Kevin Munnelly

Kevin Munnelly
Gen9

Ron Weiss

Ron Weiss
MIT

Sean Sutcliffe

Sean Sutcliffe
Green Biologics

Tom Knight

Tom Knight
Gingko Bioworks

Speakers

Alexia Chandor-Proust

Alexia Chandor-Proust
BGene Genetics

Andreas Meyer

Andreas Meyer
FGen

Axel Trefzer

Axel Trefzer
Thermo Fisher

Beatriz San Martin

Beatriz San Martin
Fieldfisher

Bethan Wolfenden

Bethan Woldenden
Bento Bioworks

Chris Thorne

Chris Thorne
Horizon Discovery

Darren Platt

Darren Platt
Amyris

Ellen Jorgensen

Ellen Jorgensen
Genspace NYC

Emily Leproust

Emily Leproust
Twist Bioscience

Eric Steinmetz

Eric Steinmetz
Lucigen

Gernot Abel

Gernot Abel
Novozymes

Hans Genee

Hans Genee
Biosyntia

Henrik Hagemann

Henrik Hagemann
CustoMem

James Field

James Field
LabGenius

James Stirling

James Stirling
Imperial College

James Taylor

James Taylor
Precision NanoSystems

Jasmina Aganovic

Jasmina Aganovic
AOBiome

Jemma Redmond

Jemma Redmond
Ourobotics

Jonathan Kotula

Jonathan Kotula
Synlogic

Josko Bobanovic

Josko Bobanovic
Sofinnova Partners

Karl Handelsman

Karl Handelsman
Codon Capital

Kathryn Owen

Kathryn Owen
Imperial Innovations

Katrin Burt

Katrin Burt
Syngenta

Marcelo Kern

Marcelo Kern
GlaxoSmithKline

Mark Wigglesworth

Mark Wigglesworth
AstraZeneca

Michael Roberts

Michael Roberts
Synpromics

Nathan Wood

Nathan Wood
SGI-DNA

Nigel Fleming

Nigel Fleming
G2B Pharma

Noga Qvit-Raz

Noga Qvit-Raz
TopgeniX

Oliver Sexton

Oliver Sexton
Rainbow Seed Fund

Orkan Telhan

Orkan Telhan
Biorealize

Paul Feldstein

Paul Feldstein
Circularis

Paul Freemont

Paul Freemont
SynbiCITE

Peter Widdowson

Peter Widdowson
Quethera

Petra Oyston

Petra Oyston
DSTL

Piers Millet

Piers Millet
Biosecure

Randy Rettberg

Randy Rettberg
iGEM

Ravi Sachidanandam

Ravi Sachidanandam
Girihlet

Remi Bernard

Remi Bernard
DEINOVE

Richard Hammond

Richard Hammond
Cambridge Consultants

Richard Kitney

Richard Kitney
SynbiCITE

Rob Carlson

Rob Carlson
Bioeconomy Capital

Ryan Burnette

Ryan Burnette
AT-RISK International

Sean Ward

Sean Ward
Synthace

Stephan Herrera

Stephan Herrera
Evolva

Ted Fjallman

Ted Fjallman
Prokarium

Veronique de Bruijn

Veronique de Bruijn
Icos Capital

Xavier Duportet

Xavier Duportet
Eligo Bioscience

Yvonne Linney

Yvonne Linney
Transcriptic

Advisory Committee

Barbara Harvey

Barbara Harvey
Novozymes

Bethan Wolfenden

Bethan Woldenden
Bento Bioworks

David McElroy

David McElroy
Ingenza

John Cumbers

John Cumbers
SynBioBeta

Karl Handelsman

Karl Handelsman
Codon Capital

Kathryn Owen

Kathryn Owen
Imperial Innovations

Paul Freemont

Paul Freemont
SynbiCITE

Richard Kitney

Richard Kitney
SynbiCITE

Xavier Duportet

Xavier Duportet
Eligo Bioscience

Schedule:

Wednesday April 6th, 2016 

Our Keynote will talk about the need for modeling of biological systems if we’re going to build a robust industry around the engineering of biology. He’ll use examples from Intel and the electronics industry to explain what the future might hold for synthetic biologists’ wanting to engineer complex biological systems.

Speaker: Tom Knight, Ginkgo Bioworks

In 1996, Tom Knight presented to DARPA a set of slides that became the basis for what we now call the Field of the Synthetic Biology.  Later, his PhD student at the time, Ron Weiss together with Tom, laid the foundations for the scientific pursuit of reliably-engineered biological systems.  In this Fireside Chat, Tom and Ron will look back on the last 20 years of the field and look forward to the next 20 years.

Speakers: Tom Knight, Ginkgo Bioworks & Ron Weiss, MIT

Without investment, no biotech company could ever get off the ground. But what are investors looking for? What is the best stage to raise capital, and who should you be talking to? What are the global trends in synthetic biology investment and how will they affect the industry? Whether you are an entrepreneur with a plan, an investor with a checkbook, or a CEO with acquisition plans, this is the panel for you.

Moderator: Josko Bobanovic, Sofinnova
Panelists:
Veronique de Bruijn, IcosCapital,  Katrin Burt, Syngenta, Karl Handelsman, Codon Capital, Kathryn Owen, Imperial Innovations, Oliver Sexton, Midven

No one knows what the future will bring, but this session will give you a pretty good idea. Covering the present and future of synthetic biology, tackling problems from food, vitamins, information storage, to high-value molecule fermentation for the production of biofuels and specialty chemicals. Our speakers will give an insight into the bleeding edge of innovation.

Moderator: Rosalind Le Feuvre, SYNBIOCHEM
2:55PM – 3:05 PM: Rémi Bernard, Deinove
3:05 PM – 3:15 PM: Hans Genee, Biosyntia
3:15 PM – 3:25 PM: Stephan Herrera, Evolva
3:25 PM – 3:35 PM: Darren Platt, Amyris
3:35 PM – 3:45 PM: Axel Trefzer, Thermo Fisher

This is a seminal moment in the history of biology.  Our ability to read, write, and rewrite the DNA code of life makes it possible to engineer all manner of organisms ranging from microbes to plants to insect to animals.  Similar to semiconductor technology that gave rise to smartphones and the web, the powerful tool of synthetic biology gives us the ability to discover solutions that make life better – whether it is apples that don’t brown, customized anti-aging products made from your own DNA, or biomaterials generated from waste.  In this fireside chat, Ena and Daisy will discuss the game-changing possibilities and implications of synthetic biology for consumer products , and ask what good design might mean in this space.

Speakers: Ena Cratsenburg, Intrexon & Alexandra Daisy Ginsberg, Royal College of Art

Synthetic Biology offers the potential to revolutionize many industries, but the one at the front both in terms of opportunity, ability to do good, and market size is the production of bio-based pharma and cell therapies. In this session, you’ll learn about T-cell receptors, CRISPR/Cas9 screening for cancer-causing mutations and other applications of synthetic biology for making people better.

Moderator: Nigel Fleming, G2B Pharma
4:55 PM – 5:05 PM: Ted Fjallman, Prokarium
5:05 PM – 5:15 PM: Marcelo Kern, GlaxoSmithKline
5:15 PM – 5:25 PM: Ravi Sachidanandam, Girihlet
5:25 PM – 5:35 PM: Chris Thorne, Horizon Discovery
5:35 PM – 5:45 PM: Mark Wigglesworth, AstraZeneca

Thursday April 7th, 2016 

Many great insights have their genesis in a casual comment, and our fireside chats aim to replicate this feeling of informal innovation. Industry thought leaders will discuss, live on stage, hot topics of the day in a relaxed setting. Interested in hearing opinions on upcoming trends? Potential shifts in the field? Or even just asking some tricky questions? This is your chance.

Speakers: Kevin Munnelly, Gen9, Barbara Harvey, Novozymes, and Sean Sutcliffe, Green Biologics

As synthetic biology grows as a field, the practitioners continue to take a broader view – how does our work benefit society as a whole? How can we ensure society is aware of this? This panel discussion will cover responsible innovation: understanding risks and benefits, communicating this to the public, and some cautionary lessons which have been learned.

Moderator: Piers Millett, Biosecure
Panelists: Ryan Burnette, AT-RISK International, Paul Freemont, SynbiCITE, Beatriz San Martin, Fieldfisher, Joyce Tait, Innogen Institute

Don’t blink or you’ll miss it! Our industry-leading speakers will have five minutes to update the audience on their latest developments and news, making this session perfect for gaining a rapid-fire overview of the current state of play.

Moderator: Petra Oyston, DSTL
11:40 AM – 11:45 AM: Gernot Abel, Novozymes
11:45 AM – 11:50 AM: Rob Carlson, Bioeconomy Capital
11:50 AM – 11:55 AM: Lionel Clarke, UK Synthetic Biology Leadership Council
11:55 AM – 12:00 PM: Henrik Hagemann, CustoMem
12:00 PM – 12:05 PM: Keira Havens, The One Sky Initiative
12:05 PM – 12:10 PM: Ellen Jorgensen, Genspace
12:10 PM – 12:15 PM: 
Randy Rettberg, iGEM
12:15 PM – 12:20 PM: 
Peter Widdowson, Quethera
12:20 PM – 12:25 PM: 
Nathan Wood, SGI-DNA

Engineering biology wouldn’t be possible without innovative genetic tools — and these companies are at the forefront of building new tools to simplify and scale the design‐build‐test cycle. You’ll be able to listen and engage with companies offering novel genetic engineering techniques, ultra-high throughput screening, and custom biocatalysts.

Moderator: Andy Boyce, Knowledge Transfer Network
2:00 PM – 2:10 PM: Alexia Chandor-Proust, BGene Genetics
2:10 PM – 2:20 PM: Paul Feldstein, Circularis
2:20 PM – 2:30 PM: James Field, LabGenius
2:30 PM – 2:40 PM: Andreas Meyer, FGen
2:40 PM – 2:50 PM: Michael Roberts, Synpromics
2:50 PM – 3:00 PM: Eric Steinmetz, Lucigen
3:00 PM – 3:10 PM: 
Dek Woolfson, BrisSynBio

Speed, reproducibility, efficiency, and value. Robotics allows experiments to be performed quickly and reproducibly, cloud systems let scientists outsource the actual process of experimentation, and machine learning offers the potential for automated data analysis and creation of hypothesis. What changes will these technologies bring, how will they affect synthetic biology, and who are the leaders in bringing it to market? Come along and find out in this session.
This Session is Sponsored by Cambridge Consultants

Moderator: Richard Hammond, Cambridge Consultants
3:15 PM – 3:25 PM: Xin Liu, Sphere Fluidics
3:25 PM – 3:35 PM: Jemma Redmond, Ourobotics
3:35 PM – 3:45 PM: James Taylor, Precision NanoSystems
3:45 PM – 3:55 PM: Orkan Telhan, Biorealize
3:55 PM – 4:05 PM: Sean Ward, Synthace
4:05 PM – 4:15 PM: Bethan Wolfenden, Bento Bioworks

The human microbiome is the community of microbes that colonize the human body.  This has been an exciting area of growth over the past decade. In recent years, a number of companies have made advances in the engineering of these microbes for new applications. In this session, we will hear from companies engineering and undertaking genetic engineering to make antimicrobials using CRISPR/Cas9, personal care products, like sunscreens to provide UV protection, or engineering gut bacteria to combat metabolic disease.

Moderator: Yvonne Linney, Transcriptic
5:05 PM – 5:15 PM: Jasmina Aganovic, AOBiome
5:15 PM – 5:25 PM: Xavier Duportet, Eligo Bioscience
5:25 PM – 3:35 PM: Jonathan Kotula, Synlogic
5:35 PM – 5:45 PM: Noga Qvit-Raz, TopgeniX

Friday April 8th, 2016

After SynBioBeta London 2016, join your peers for a special investor breakfast at the House of Lords, hosted by the The Rt Hon. Lord Willetts. Don’t miss this opportunity to connect and have discussions with like-minded entrepreneurs, investors, and thought leaders whilst enjoying a full english breakfast.
If you’re attending SynBioBeta London 2016 and want more opportunities to connect with people at the event, then you will not want to miss the Networking Cruise on the River Thames. Hosted by SynBioBeta and SynbiCITE, this event will give you ample time to connect while you enjoy refreshments aboard the M.V. Harmony, and take in the impressive sights of London.

Partners: